In this episode, Global Trac Solutions, Inc. CEO, David Flores, has the very distinct pleasure of being joined by Carlos Tanner, founder of the Ayahuasca Foundation in Iquitos, Peru.
Similar Posts
Entheon Biomedical CEO Interview With Timothy Ko | (CSE: ENBI) (OTC: ENTBF) | DMT Vs. Psilocybin
Entheon Biomedical CEO Timothy Ko (CSE: ENBI) (OTC: ENTBF) (“Entheon” or the “Company”), a biotechnology company focused on developing psychedelic medicines to treat addiction with DMT.
Entheon Biomedical is pioneering a leading-edge addiction recovery solution that harnesses and optimizes the therapeutic potential of the DMT molecule. Entheon exists to invert the addiction-recovery ratio, turning the ‘untreatable case’ and ‘lost cause’ from the norm to the exception.
Entheon Biomedical is developing a DMT-assisted therapeutic protocol that will be specifically tailored to address the core mechanisms underlying drug-seeking and using behavior. Our chief aim is to provide an effective and scalable therapeutic protocol that will serve as a vital resource for those afflicted with a substance-use disorder, and who are wanting to reclaim their lives.
Entheon’s DMT clinical trial later this year will put it in direct competition with MindMed (MMED /MMEDF), who is also planning on launching a DMT clinical trial later this year.
I hope you guys found some value in this and I’ll keep you posted for more changes!
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
For any potential collaborations, please reach us at: thepsychedelicinvestor@gmail.com
Music: www.bensound.com
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
The Psychedelic Investor was compensated $1,000 by Future Money Trends for the making of this video on Entheon Biomedical. James (The Psychedelic Investor) does not own a position in Entheon Biomedical and will not open one for at least 30 days after publication of this video.
https://entheonbiomedical.com/
CSE: ENBI | OTCQB: ENTBF
This video was conducted on behalf of Entheon Biomedical, and was funded by Gold Standard Media LLC. For our full disclaimer, please visit: https://www.goldstandardir.com/entheon-biomedical-disclaimer-85/
#EntheonBiomedical #Entheon #PsychedelicStocks
Interview with Julianne Keu, Psychedelic YouTuber
In this episode, YouTuber Julianne Keu discusses how she went from microdosing psilocybin to participating in shamanic doses to explore the mystical and spiritual universe.
Why the Psychedelic Drug Market is Experiencing Major Growth
David Flores, CEO of Global Trac Solutions (PSYC), joins Cheddar…
Ask A Psychedelic Guide
We welcome back Nick Levich for our “Ask a Psychedelic Professional” series and as part of our “Ask a Psychedelic Guide” episode.
Psychedelic Spotlight Interview with Douglas K. Gordon
In this episode of the Psychedelic Spotlight podcast, we connect…
Could Psilocybin End Our Addiction Crisis?
Two doses of psilocybin over a period of eight weeks significantly reduced alcohol use and cravings for alcoholics. That’s according to early results of a New York University phase 2 study.